NKGen Biotech Inc [NASDAQ: NKGN] gained 32.91% on the last trading session, reaching $1.47 price per share at the time.
If compared to the average trading volume of 2.90M shares, NKGN reached a trading volume of 23642921 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Trading performance analysis for NKGN stock
NKGen Biotech Inc [NKGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.55. With this latest performance, NKGN shares dropped by -33.78% in over the last four-week period, additionally sinking by -51.00% over the last 6 months – not to mention a drop of -85.53% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NKGN stock in for the last two-week period is set at 50.63, with the RSI for the last a single of trading hit 55.04, and the three-weeks RSI is set at 48.66 for NKGen Biotech Inc [NKGN]. The present Moving Average for the last 50 days of trading for this stock 1.5076, while it was recorded at 1.1352 for the last single week of trading, and 4.7587 for the last 200 days.
NKGen Biotech Inc [NKGN]: A deeper dive into fundamental analysis
NKGen Biotech Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.05 and a Current Ratio set at 0.05.
An analysis of Institutional ownership at NKGen Biotech Inc [NKGN]
The top three institutional holders of NKGN stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in NKGN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in NKGN stock with ownership which is approximately 5.8386%.
